Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01322.x/abstract

Elimination of hepatitis B virus surface antigen and appearance of neutralizing

antibodies in chronically infected patients without viral clearance

Z.-H. Zhang1,5, L. Li1, X.-P. Zhao1, D. Glebe2, C. M. Bremer2, Z.-M. Zhang1,

Y.-J. Tian1, B.-J. Wang1, Y. Yang1, W. Gerlich2, M. Roggendorf3, X. Li5, M.

Lu3,4, D.-L. Yang1

Article first published online: 31 AUG 2010

DOI: 10.1111/j.1365-2893.2010.01322.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 6, pages 424–433, June 2011

Summary.  Seroconversion from hepatitis B surface antigen (HBsAg) to

antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B

virus (HBV) infection. Here, two HBV-infected patients with seroconversion to

anti-HBs were found to be persistently positive for HBeAg and HBV DNA.

Immunohistology of liver biopsies confirmed the expression of HBV proteins in

the liver of one patient. The neutralizing ability of anti-HBs in patient sera

was demonstrated by blocking HBV infection of primary tupaia hepatocytes.

Analysis of the HBsAg-encoding region of HBV isolates from patients indicated

the coexistence of heterogeneous HBV genomes in patients. The majority of

recombinant variant HBsAg was reactive in HBsAg assays and was able to bind to

anti-HBs. Circulating immune complexes (CIC) of HBsAg in patient sera could be

detected by polyethylene glycol precipitation and trypsin digestion. Thus,

neutralizing anti-HBs may appear in chronic HBV carriers for long periods but

does not necessarily lead to complete viral clearance.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01322.x/abstract

Elimination of hepatitis B virus surface antigen and appearance of neutralizing

antibodies in chronically infected patients without viral clearance

Z.-H. Zhang1,5, L. Li1, X.-P. Zhao1, D. Glebe2, C. M. Bremer2, Z.-M. Zhang1,

Y.-J. Tian1, B.-J. Wang1, Y. Yang1, W. Gerlich2, M. Roggendorf3, X. Li5, M.

Lu3,4, D.-L. Yang1

Article first published online: 31 AUG 2010

DOI: 10.1111/j.1365-2893.2010.01322.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 6, pages 424–433, June 2011

Summary.  Seroconversion from hepatitis B surface antigen (HBsAg) to

antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B

virus (HBV) infection. Here, two HBV-infected patients with seroconversion to

anti-HBs were found to be persistently positive for HBeAg and HBV DNA.

Immunohistology of liver biopsies confirmed the expression of HBV proteins in

the liver of one patient. The neutralizing ability of anti-HBs in patient sera

was demonstrated by blocking HBV infection of primary tupaia hepatocytes.

Analysis of the HBsAg-encoding region of HBV isolates from patients indicated

the coexistence of heterogeneous HBV genomes in patients. The majority of

recombinant variant HBsAg was reactive in HBsAg assays and was able to bind to

anti-HBs. Circulating immune complexes (CIC) of HBsAg in patient sera could be

detected by polyethylene glycol precipitation and trypsin digestion. Thus,

neutralizing anti-HBs may appear in chronic HBV carriers for long periods but

does not necessarily lead to complete viral clearance.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01322.x/abstract

Elimination of hepatitis B virus surface antigen and appearance of neutralizing

antibodies in chronically infected patients without viral clearance

Z.-H. Zhang1,5, L. Li1, X.-P. Zhao1, D. Glebe2, C. M. Bremer2, Z.-M. Zhang1,

Y.-J. Tian1, B.-J. Wang1, Y. Yang1, W. Gerlich2, M. Roggendorf3, X. Li5, M.

Lu3,4, D.-L. Yang1

Article first published online: 31 AUG 2010

DOI: 10.1111/j.1365-2893.2010.01322.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 6, pages 424–433, June 2011

Summary.  Seroconversion from hepatitis B surface antigen (HBsAg) to

antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B

virus (HBV) infection. Here, two HBV-infected patients with seroconversion to

anti-HBs were found to be persistently positive for HBeAg and HBV DNA.

Immunohistology of liver biopsies confirmed the expression of HBV proteins in

the liver of one patient. The neutralizing ability of anti-HBs in patient sera

was demonstrated by blocking HBV infection of primary tupaia hepatocytes.

Analysis of the HBsAg-encoding region of HBV isolates from patients indicated

the coexistence of heterogeneous HBV genomes in patients. The majority of

recombinant variant HBsAg was reactive in HBsAg assays and was able to bind to

anti-HBs. Circulating immune complexes (CIC) of HBsAg in patient sera could be

detected by polyethylene glycol precipitation and trypsin digestion. Thus,

neutralizing anti-HBs may appear in chronic HBV carriers for long periods but

does not necessarily lead to complete viral clearance.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01322.x/abstract

Elimination of hepatitis B virus surface antigen and appearance of neutralizing

antibodies in chronically infected patients without viral clearance

Z.-H. Zhang1,5, L. Li1, X.-P. Zhao1, D. Glebe2, C. M. Bremer2, Z.-M. Zhang1,

Y.-J. Tian1, B.-J. Wang1, Y. Yang1, W. Gerlich2, M. Roggendorf3, X. Li5, M.

Lu3,4, D.-L. Yang1

Article first published online: 31 AUG 2010

DOI: 10.1111/j.1365-2893.2010.01322.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 6, pages 424–433, June 2011

Summary.  Seroconversion from hepatitis B surface antigen (HBsAg) to

antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B

virus (HBV) infection. Here, two HBV-infected patients with seroconversion to

anti-HBs were found to be persistently positive for HBeAg and HBV DNA.

Immunohistology of liver biopsies confirmed the expression of HBV proteins in

the liver of one patient. The neutralizing ability of anti-HBs in patient sera

was demonstrated by blocking HBV infection of primary tupaia hepatocytes.

Analysis of the HBsAg-encoding region of HBV isolates from patients indicated

the coexistence of heterogeneous HBV genomes in patients. The majority of

recombinant variant HBsAg was reactive in HBsAg assays and was able to bind to

anti-HBs. Circulating immune complexes (CIC) of HBsAg in patient sera could be

detected by polyethylene glycol precipitation and trypsin digestion. Thus,

neutralizing anti-HBs may appear in chronic HBV carriers for long periods but

does not necessarily lead to complete viral clearance.